<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513617</url>
  </required_header>
  <id_info>
    <org_study_id>485</org_study_id>
    <secondary_id>U54HL070587-04</secondary_id>
    <nct_id>NCT00513617</nct_id>
  </id_info>
  <brief_title>Effectiveness of Arginine as a Treatment for Sickle Cell Anemia</brief_title>
  <acronym>Arginine</acronym>
  <official_title>Arginine Supplementation in Sickle Cell Anemia: Physiological and Prophylactic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital &amp; Research Center Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease
      that can cause intense pain episodes. This study will evaluate the effectiveness of the
      nutritional supplement arginine at improving blood cell function and disease symptoms in
      people with SCD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and
      intense episodes of pain that are called &quot;sickle cell crises.&quot; SCD is caused by an abnormal
      type of hemoglobin, which is a protein inside red blood cells that carries oxygen. In people
      with SCD, the abnormal hemoglobin distorts the shape of the red blood cells. This causes the
      red blood cells to clump together, decreasing blood flow and oxygen delivery to the body's
      tissues. The reduced levels of oxygen can lead to sickle cell crises and tissue damage.
      Hemolysis, the destruction of red blood cells, is also a hallmark of SCD. During hemolysis,
      hemoglobin is released into the bloodstream, where it removes nitric oxide (NO), a natural
      chemical in the body that expands blood vessels. Arginase, another protein released during
      hemolysis, removes arginine from the bloodstream, which can also lead to decreased NO levels.
      The lack of NO constricts blood vessels, further contributing to painful sickle cell crises.
      Arginine supplementation may increase healthy hemoglobin and NO production and, in turn,
      prevent or reduce sickle cell crises. The purpose of this study is to evaluate the
      effectiveness of arginine at increasing NO levels, improving red blood cell function, and
      reducing hospitalizations and pain medication use in people with SCD.

      This study will enroll children and adults with SCD. Participants will be randomly assigned
      to receive twice daily doses of either a low dose of arginine, a high dose of arginine, or
      placebo for 12 weeks. Study visits will occur at baseline, three times during Month 1, and
      Weeks 8, 12, 14, and 16. Each study visit will include an echocardiogram to measure heart
      activity, blood collection, and a medical history review to identify adverse events, pain
      medication usage, headaches, emergency department visits, and hospitalizations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gardos Channel Activity</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Gardos channel activity: a calcium (Ca2+)-activated K+ channel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nitric Oxide</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Nitric oxide from plasma amino acids</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Corpuscular Hemoglobin Concentration</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Mean corpuscular hemoglobin concentration as measured by an Advia machine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Soluble Vascular Cell Adhesion Molecule</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Soluble vascular cell adhesion molecule (sVCAM) a vascular adhesion molecule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-iso-PGF2a</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>8-iso-PGF2a is a measure of lipid peroxidation and oxidative damage in vivo measured by enzyme immunoassay kit from Cayman chemical</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelin-1</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Endothelin-1 is a potent vasoconstrictor and pro-inflammatory agent which is elevated in SCD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal Hemoglobin</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Fetal hemoglobin (HbF) as measured by the Advia machine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Anemia, Sickle Cell</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.05 g/kg/day Arginine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.10 g/kg/day Arginine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No Arginine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine</intervention_name>
    <description>Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.</description>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of H SS or S-beta thalassemia

          -  History of at least one vaso-occlusive pain event in the 12 months prior to study
             entry

          -  Regular compliance with comprehensive medical care

          -  In a steady disease state and not in the midst of any acute complication due to SCD at
             study entry

        Exclusion Criteria:

          -  Inability to take or tolerate oral medications

          -  Liver dysfunction (i.e., SGPT level greater than or equal to two times the normal
             limit and albumin level less than or equal to 3.2 g/dL)

          -  Kidney dysfunction ( i.e., creatinine level greater than or equal to 1.2 mg/dL for
             children and greater than or equal to 1.4 mg/dL for adults)

          -  Allergy to arginine

          -  Pregnant

          -  Received a blood transfusion within the 90 days prior to study entry

          -  More than 10 hospital admissions for pain in the 12 months prior to study entry

          -  Daily use of opioids and experiencing unstable pain that interferes with work or daily
             routine

          -  Required more than 3 hospital admissions and more than 10 emergency department/day
             hospital visits in the 12 months prior to study entry

          -  Received treatment with hydroxyurea within the 90 days prior to study entry

          -  Received treatment with any investigational drug in the 90 days prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian McMahon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rathi Iyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center (Pediatric)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolyn Bigelow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center (Adult)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lennette Benjamin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Fabry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Moulton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Montefiore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Smith-Whitley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura DeCastro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Ataga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samir K. Ballas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sal Bertalone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norton Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlton Dampier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Christopher's Childrens Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Mentzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Winfred Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude's Childrens Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Reiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Rutherford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Medical Center Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Hassell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan Parkhurst Cain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Oakland and Research Institute</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado at Denver and Health Sciences Center--Sickle Cell Treatment and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center (Adult)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center (Pediatric)</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Children's Research Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19444</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>February 23, 2009</results_first_submitted>
  <results_first_submitted_qc>June 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2009</results_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <name_title>Lori Styles/Principal Investigator</name_title>
    <organization>Childrens Hospital of Oakland and Research Institute</organization>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Anemia</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Vaso Occlusive Events</keyword>
  <keyword>Arginine Supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrolled subjects at participating sites from May 2004 through July 2007. Sites consisted of sickle cell treatment centers from across the United States.</recruitment_details>
      <pre_assignment_details>All subjects were to be without hydroxyurea, transfusion, and arginine for 90 days prior to enrollment. Prior to randomization, blood was drawn for baseline efficacy and safety measurements.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose</title>
          <description>0.05 g/kg/day of Arginine in capsule form</description>
        </group>
        <group group_id="P2">
          <title>High Dose</title>
          <description>0.10 g/kg/day of Arginine in capsule form</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose</title>
          <description>0.05 g/kg/day of Arginine in capsule form</description>
        </group>
        <group group_id="B2">
          <title>High Dose</title>
          <description>0.10 g/kg/day of Arginine in capsule form</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" spread="12.85"/>
                    <measurement group_id="B2" value="20.0" spread="10.01"/>
                    <measurement group_id="B3" value="21.0" spread="11.49"/>
                    <measurement group_id="B4" value="23.2" spread="11.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="109.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Genotype of SCD</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sickle cell S-Beta Thalassemia (SB0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sickle cell Anemia (SS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="102.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gardos Channel Activity</title>
        <description>Gardos channel activity: a calcium (Ca2+)–activated K+ channel</description>
        <time_frame>12 weeks after randomization</time_frame>
        <population>All subjects that were randomized and dosed - Intent to Treat (ITT) No imputation used.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>0.05 g/kg/day of Arginine in capsule form</description>
          </group>
          <group group_id="O2">
            <title>High Dose</title>
            <description>0.10 g/kg/day of Arginine in capsule form</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Gardos Channel Activity</title>
          <description>Gardos channel activity: a calcium (Ca2+)–activated K+ channel</description>
          <population>All subjects that were randomized and dosed - Intent to Treat (ITT) No imputation used.</population>
          <units>mmol/10^13 cells x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0342" spread="0.2341"/>
                    <measurement group_id="O2" value="0.0043" spread="0.3028"/>
                    <measurement group_id="O3" value="0.1076" spread="0.2822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference between high vs. placebo and low vs. placebo in change from baseline at Week 12 post-randomization. Separate models were fit for pediatric and adult populations, however the combined population is entered here.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <p_value_desc>Alpha was set at 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Null is tested using the F-test from a random effects longitudinal mixed model, with treatment and baseline measurement as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1254</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0705</dispersion_value>
            <estimate_desc>Placebo was subtracted from the Low dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference between high vs. placebo and low vs. placebo in change from baseline at Week 12 post-randomization. Separate models were fit for pediatric and adult populations, however the combined population is entered here.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <p_value_desc>Alpha was set at 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Null is tested using the F-test from a random effects longitudinal mixed model, with treatment and baseline measurement as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0980</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0713</dispersion_value>
            <estimate_desc>Placebo was subtracted from High dose</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soluble Vascular Cell Adhesion Molecule</title>
        <description>Soluble vascular cell adhesion molecule (sVCAM) a vascular adhesion molecule</description>
        <time_frame>12 weeks after randomization</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nitric Oxide</title>
        <description>Nitric oxide from plasma amino acids</description>
        <time_frame>12 weeks after randomization</time_frame>
        <population>All subjects that were randomized and dosed - ITT No imputation used.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>0.05 g/kg/day of Arginine in capsule form</description>
          </group>
          <group group_id="O2">
            <title>High Dose</title>
            <description>0.10 g/kg/day of Arginine in capsule form</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Nitric Oxide</title>
          <description>Nitric oxide from plasma amino acids</description>
          <population>All subjects that were randomized and dosed - ITT No imputation used.</population>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8697" spread="15.7574"/>
                    <measurement group_id="O2" value="2.9250" spread="11.1646"/>
                    <measurement group_id="O3" value="-3.0265" spread="18.6887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference between high vs. placebo and low vs. placebo in change from baseline at Week 12 post-randomization. Separate models were fit for pediatric and adult populations, however the combined population is entered here.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.915</p_value>
            <p_value_desc>Alpha was set at 0.5</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Null is tested using the F-test from a random effects longitudinal mixed model, with treatment and baseline measurement as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1826</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0713</dispersion_value>
            <estimate_desc>Placebo subtracted from Low dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference between high vs. placebo and low vs. placebo in change from baseline at Week 12 post-randomization. Separate models were fit for pediatric and adult populations, however the combined population is entered here.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.918</p_value>
            <p_value_desc>Alpha was set at 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Null is tested using the F-test from a random effects longitudinal mixed model, with treatment and baseline measurement as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.3582</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.1047</dispersion_value>
            <estimate_desc>Placebo subtracted from High dose</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Corpuscular Hemoglobin Concentration</title>
        <description>Mean corpuscular hemoglobin concentration as measured by an Advia machine</description>
        <time_frame>12 weeks after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose</title>
            <description>0.05 g/kg/day of Arginine in capsule form</description>
          </group>
          <group group_id="O2">
            <title>High Dose</title>
            <description>0.10 g/kg/day of Arginine in capsule form</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Corpuscular Hemoglobin Concentration</title>
          <description>Mean corpuscular hemoglobin concentration as measured by an Advia machine</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8485" spread="6.3092"/>
                    <measurement group_id="O2" value="0.7692" spread="2.2165"/>
                    <measurement group_id="O3" value="-0.0705" spread="1.4422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference between high vs. placebo and low vs. placebo in change from baseline at Week 12 post-randomization. Separate models were fit for pediatric and adult populations, however the combined population is entered here.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>Alpha was set at 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Null is tested using the F-test from a random effects longitudinal mixed model, with treatment and baseline measurement as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.7867</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1101</dispersion_value>
            <estimate_desc>Placebo subtracted from Low dose</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference between high vs. placebo and low vs. placebo in change from baseline at Week 12 post-randomization. Separate models were fit for pediatric and adult populations, however the combined population is entered here.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.557</p_value>
            <p_value_desc>Alpha was set at 0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Null is tested using the F-test from a random effects longitudinal mixed model, with treatment and baseline measurement as fixed effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5213</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1553</dispersion_value>
            <estimate_desc>Placebo subtracted from High dose</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>8-iso-PGF2a</title>
        <description>8-iso-PGF2a is a measure of lipid peroxidation and oxidative damage in vivo measured by enzyme immunoassay kit from Cayman chemical</description>
        <time_frame>12 weeks after randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelin-1</title>
        <description>Endothelin-1 is a potent vasoconstrictor and pro-inflammatory agent which is elevated in SCD patients</description>
        <time_frame>12 weeks after randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fetal Hemoglobin</title>
        <description>Fetal hemoglobin (HbF) as measured by the Advia machine</description>
        <time_frame>12 weeks after randomization</time_frame>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Adult enrollment was slower than expected. Adult subjects were more likely than peds to drop-out due to SCD pain crisis. Higher doses of arginine (such as used in animal studies) were limited by number of daily pills required.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Karen Kesler, PhD</name_or_title>
      <organization>Rho Federal Systems Division</organization>
      <phone>919-408-8000 ext 244</phone>
      <email>karen_kesler@rhoworld.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

